{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:49:15Z","timestamp":1790790555323,"version":"4.1.0"},"reference-count":139,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although an increasing number of patients suffering from mental illnesses self-medicate with cannabis, current knowledge about the efficacy and safety of cannabis-based medicine in psychiatry is still extremely limited. So far, no cannabis-based finished product has been approved for the treatment of a mental illness. There is increasing evidence that cannabinoids may improve symptoms in autism spectrum disorder (ASD), Tourette syndrome (TS), anxiety disorders, and post-traumatic stress disorder (PTSD). According to surveys, patients often use cannabinoids to improve mood, sleep, and symptoms of attention deficit\/hyperactivity disorder (ADHD). There is evidence suggesting that tetrahydrocannabinol (THC) and THC-containing cannabis extracts, such as nabiximols, can be used as substitutes in patients with cannabis use disorder.<\/jats:p><jats:p>Preliminary evidence also suggests an involvement of the endocannabinoid system (ECS) in the pathophysiology of TS, ADHD, and PTSD. Since the ECS is the most important neuromodulatory system in the brain, it possibly induces beneficial effects of cannabinoids by alterations in other neurotransmitter systems. Finally, the ECS is an important stress management system. Thus, cannabinoids may improve symptoms in patients with mental illnesses by reducing stress.<\/jats:p><jats:p>Practically, cannabis-based treatment in patients with psychiatric disorders does not differ from other indications. The starting dose of THC-containing products should be low (1\u20132.5\u2009mg THC\/day), and the dose should be up-titrated slowly (by 1\u20132.5\u2009mg every 3\u20135 days). The average daily dose is 10\u201320\u2009mg THC. In contrast, cannabidiol (CBD) is mainly used in high doses&gt;400\u2009mg\/day.<\/jats:p>","DOI":"10.1055\/a-2256-0098","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:12:36Z","timestamp":1709338356000},"page":"104-114","source":"Crossref","is-referenced-by-count":25,"title":["Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature"],"prefix":"10.1055","volume":"57","author":[{"given":"Kirsten R.","family":"M\u00fcller-Vahl","sequence":"additional","affiliation":[{"name":"Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"ref2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis","volume":"6","author":"N Black","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12888-019-2409-8","article-title":"Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review","volume":"20","author":"J Sarris","year":"2020","journal-title":"BMC Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jpsychires.2021.05.044","article-title":"Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials","volume":"140","author":"K A McKee","year":"2021","journal-title":"J Psychiatr Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.9758\/cpn.2017.15.4.301","article-title":"A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders","volume":"15","author":"K Lim","year":"2017","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/02791072.2013.805976","article-title":"The medicinal use of cannabis and cannabinoids--an international cross-sectional survey on administration forms","volume":"45","author":"A Hazekamp","year":"2013","journal-title":"J Psychoactive Drugs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-022-00666-w","article-title":"Medical cannabis use in Australia: Consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)","volume":"19","author":"N Lintzeris","year":"2022","journal-title":"Harm Reduction Journal"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/21501319221129734","article-title":"An observational cross-sectional survey exploring the indications for and responses to medical marijuana use in certified patients in Pennsylvania","author":"D Kimless","year":"2022","journal-title":"J Prim Care Community Health"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5694\/mja17.01247","article-title":"Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS-16)","volume":"209","author":"N Lintzeris","year":"2018","journal-title":"Med J Aust"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/JCP.0000000000001179","article-title":"Cannabinoid augmentation of exposure-based psychotherapy for obsessive-compulsive disorder","volume":"40","author":"R R Kayser","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/npp.2017.305","article-title":"Enhancing endocannabinoid neurotransmission augments the efficacy of extinction training and ameliorates traumatic stress-induced behavioral alterations in rats","volume":"43","author":"M Morena","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.3390\/molecules26092774","article-title":"Cannabinoids, phenolics, terpenes and alkaloids of cannabis","volume":"26","author":"M M Radwan","year":"2021","journal-title":"Molecules"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"123133","DOI":"10.1016\/j.saa.2023.123133","article-title":"A study of major cannabinoids via Raman spectroscopy and density functional theory","volume":"303","author":"T J Wolfe","year":"2023","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"777804","DOI":"10.3389\/fphar.2021.777804","article-title":"Minor cannabinoids: Biosynthesis, molecular pharmacology and potential therapeutic uses","volume":"12","author":"K B Walsh","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(98)00392-6","article-title":"An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity","volume":"353","author":"S Ben-Shabat","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1089\/can.2015.29003.ebr","article-title":"The Cannabis sativa versus Cannabis indica debate: An interview with Ethan Russo, MD","volume":"1","author":"D Piomelli","year":"2016","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"6723","DOI":"10.3390\/molecules26216723","article-title":"Cannabinoids\u2014characteristics and potential for use in food production","volume":"26","author":"J Kanabus","year":"2021","journal-title":"Molecules"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e00682","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"D L de Almeida","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.3390\/ijms21145064","article-title":"Targeting cannabinoid receptors: Current status and prospects of natural products","volume":"21","author":"D An","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.mehy.2005.08.026","article-title":"A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol","volume":"66","author":"E Russo","year":"2006","journal-title":"Med Hypotheses"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3390\/biomedicines11082323","article-title":"Decoding the postulated entourage effect of medicinal cannabis: What it is and what it isn\u2019t","volume":"11","author":"C Christensen","year":"2023","journal-title":"Biomedicines"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","article-title":"Practical considerations in medical cannabis administration and dosing","volume":"49","author":"C A MacCallum","year":"2018","journal-title":"Eur J Intern Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejim.2021.05.002","article-title":"\"Is medical cannabis safe for my patients?\u201c A practical review of cannabis safety considerations","volume":"89","author":"C A MacCallum","year":"2021","journal-title":"Eur J Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2147\/IJGM.S275049","article-title":"Safety considerations in cannabinoid-based medicine","volume":"13","author":"S Gottschling","year":"2020","journal-title":"Int J Gen Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies","volume":"2","author":"K Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"E206","DOI":"10.1503\/cmaj.191097","article-title":"Drug interactions with cannabinoids","volume":"192","author":"T Antoniou","year":"2020","journal-title":"CMAJ"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cts.13425","article-title":"The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence","volume":"16","author":"J C Arnold","year":"2022","journal-title":"Clin Transl Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.molmed.2020.07.002","article-title":"Meet your stress management professionals: The endocannabinoids","volume":"26","author":"T A deRoon-Cassini","year":"2020","journal-title":"Trends Mol Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1111\/ejn.14407","article-title":"Modulatory effects of cannabinoids on brain neurotransmission","volume":"50","author":"K Cohen","year":"2019","journal-title":"Eur J Neurosci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41386-020-0671-6","article-title":"Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome","volume":"5","author":"K R M\u00fcller-Vahl","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/can.2016.0009","article-title":"Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes","volume":"1","author":"E B Russo","year":"2016","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"41","author":"I M Linares","year":"2019","journal-title":"Braz J Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2017.00259","article-title":"Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life","volume":"8","author":"A W Zuardi","year":"2017","journal-title":"Front Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.japh.2019.11.008","article-title":"Use of cannabidiol in anxiety and anxiety-related disorders","volume":"60","author":"J W Skelley","year":"2020","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"E M Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1142680","DOI":"10.3389\/fphar.2023.1142680","article-title":"Medicinal cannabis for psychiatry-related conditions: An overview of current Australian prescribing","volume":"14","author":"E A Cairns","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jpsychires.2007.01.002","article-title":"Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence","volume":"42","author":"J D Buckner","year":"2008","journal-title":"J Psychiatr Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.26828\/cannabis.2019.01.005","article-title":"Medical cannabis use among adults in the Southeastern United States","volume":"2","author":"C A Salazar","year":"2019","journal-title":"Cannabis"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpsychires.2019.01.024","article-title":"Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users","volume":"111","author":"J Turna","year":"2019","journal-title":"J Psychiatr Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"M M Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","article-title":"Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders","volume":"10","author":"N Masataka","year":"2019","journal-title":"Front Psychol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report","volume":"25","author":"JA S Crippa","year":"2011","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.euroneuro.2022.04.003","article-title":"Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial","volume":"59","author":"C M Kwee","year":"2022","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.euroneuro.2023.04.001","article-title":"Anxiolytic effects of endocannabinoid enhancing compounds: A systematic review and meta-analysis","volume":"72","author":"CM B Kwee","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/s41386-020-00888-1","article-title":"The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: A double-blind, randomized, placebo-controlled proof-of-concept study","volume":"46","author":"M E Schmidt","year":"2021","journal-title":"Neuropsychopharmacol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e0156614","DOI":"10.1371\/journal.pone.0156614","article-title":"\"I Use weed for my ADHD\u201c: A qualitative analysis of online forum discussions on cannabis use and ADHD","volume":"11","author":"J T Mitchell","year":"2016","journal-title":"PLoS ONE"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3109\/10826084.2013.841251","article-title":"Subtypes of attention deficit-hyperactivity disorder (ADHD) and cannabis use","volume":"49","author":"M Loflin","year":"2014","journal-title":"Subst Use Misuse"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1055\/s-0042-100702","article-title":"Cannabis und cannabinoide in der medizin: Fakten und ausblick","volume":"17","author":"F Grotenhermen","year":"2016","journal-title":"Suchttherapie"},{"key":"ref51","first-page":"11","article-title":"Fitness to drive in spite (because) of THC","volume":"220","author":"P Strohbeck-K\u00fchner","year":"2007","journal-title":"Arch Kriminol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000521370","article-title":"Cannabis for the treatment of attention deficit hyperactivity disorder: A report of 3 cases","volume":"5","author":"H Mansell","year":"2022","journal-title":"Med Cannabis Cannabinoids"},{"key":"ref53","volume-title":"Successful therapy of treatment resistant adult ADHD with cannabis: Experience from a medical practice with 30 patients. In: Poster","author":"E Milz","year":"2015"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","article-title":"Cannabinoids in attention-deficit\/hyperactivity disorder: A randomised-controlled trial","volume":"27","author":"R E Cooper","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1212\/WNL.0b013e3181a2e8f6","article-title":"Altered anandamide degradation in attention-deficit\/hyperactivity disorder","volume":"72","author":"D Centonze","year":"2009","journal-title":"Neurology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.ygeno.2019.07.024","article-title":"The first evidence of an association between a polymorphism in the endocannabinoid-degrading enzyme FAAH (FAAH rs2295633) with attention deficit hyperactivity disorder","volume":"112","author":"A Ahmadalipour","year":"2020","journal-title":"Genomics"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s42238-021-00108-7","article-title":"CBD-enriched cannabis for autism spectrum disorder: An experience of a single center in Turkey and reviews of the literature","volume":"3","author":"S Bilge","year":"2021","journal-title":"J Cannabis Res"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/cns.12648","article-title":"Beneficial effects of co-ultramicronized palmitoylethanolamide\/luteolin in a mouse model of autism and in a case report of autism","volume":"23","author":"B Bertolino","year":"2017","journal-title":"CNS Neurosci Ther"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-A retrospective feasibility study","volume":"49","author":"A Aran","year":"2019","journal-title":"J Autism Dev Disord"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities","volume":"9","author":"D Barchel","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41398-022-02104-8","article-title":"Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: An open label study","volume":"12","author":"M Hacohen","year":"2022","journal-title":"Transl Psychiatry"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: A proof-of-concept randomized trial","volume":"12","author":"A Aran","year":"2021","journal-title":"Mol Autism"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"44","DOI":"10.47626\/2237-6089-2021-0396","article-title":"Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: Randomized, double-blind and controlled placebo clinical trial","volume":"26","author":"E A da Silva","year":"2022","journal-title":"Trends Psychiatry Psychother"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial","volume":"116","author":"F R Levin","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: A randomized clinical trial","volume":"71","author":"D J Allsop","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e0190768","DOI":"10.1371\/journal.pone.0190768","article-title":"Nabiximols combined with motivational enhancement\/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial","volume":"13","author":"J M Trigo","year":"2018","journal-title":"PLoS One"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamainternmed.2019.1993","article-title":"Nabiximols for the treatment of cannabis dependence: A randomized clinical trial","volume":"179","author":"N Lintzeris","year":"2019","journal-title":"JAMA Intern Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial","volume":"7","author":"T P Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S2215-0366(18)30427-9","article-title":"Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: A double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial","volume":"6","author":"D C D\u2019Souza","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.drugalcdep.2016.05.002","article-title":"Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans","volume":"164","author":"M R Lofwall","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.drugalcdep.2015.05.013","article-title":"The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone","volume":"154","author":"A Bisaga","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial","volume":"176","author":"Y L Hurd","year":"2019","journal-title":"Am J Psychiatry"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12954-021-00520-5","article-title":"Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample","volume":"18","author":"S L Kvamme","year":"2021","journal-title":"Harm Reduct J"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/add.15417","article-title":"Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: A randomized placebo-controlled trial","volume":"116","author":"V Mongeau-P\u00e9russe","year":"2021","journal-title":"Addiction"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1038\/s41386-021-01098-z","article-title":"Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: A randomized controlled trial","volume":"46","author":"F Morissette","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1089\/can.2023.0065","article-title":"Cannabinoids for substance use disorder treatment: What does the current evidence say?","volume":"8","author":"JA B Fernandes","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000527113","article-title":"Med Cannabis Cannabinoids","volume":"5","author":"Cannabinoid Conference 2022","year":"2022"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ajad.12963","article-title":"Cannabis and cannabinoids in mood and anxiety disorders: Impact on illness onset and course, and assessment of therapeutic potential","volume":"29","author":"S L Botsford","year":"2020","journal-title":"Am J Addict"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/can.2016.0007","article-title":"A cross-sectional survey of medical cannabis users: Patterns of use and perceived efficacy","volume":"1","author":"M Sexton","year":"2016","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref80","first-page":"251","article-title":"The effectiveness of cannabis flower for immediate relief from symptoms of depression","volume":"93","author":"X Li","year":"2020","journal-title":"Yale J Biol Med"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"E694","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: A randomized controlled trial","volume":"182","author":"M A Ware","year":"2010","journal-title":"CMAJ"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12991-023-00437-2","article-title":"Endocannabinergic modulation of central serotonergic activity in healthy human volunteers","volume":"22","author":"B Emons","year":"2023","journal-title":"Ann Gen Psychiatry"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3389\/fpsyt.2020.00681","article-title":"Cannabis improves obsessive-compulsive disorder-case report and review of the literature","volume":"11","author":"N Szejko","year":"2020","journal-title":"Front Psychiatry"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"100664","DOI":"10.1016\/j.jocrd.2021.100664","article-title":"Patterns of cannabis use among individuals with obsessive-compulsive disorder: Results from an internet survey","volume":"30","author":"R R Kayser","year":"2021","journal-title":"J Obsessive Compuls Relat Disord"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1176\/appi.ajp.2007.07061016","article-title":"Improvement in refractory obsessive compulsive disorder with dronabinol","volume":"165","author":"F Schindler","year":"2008","journal-title":"Am J Psychiatry"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1176\/appi.neuropsych.16030053","article-title":"Refractory OCD due to thalamic infarct with response to dronabinol","volume":"29","author":"J J Cooper","year":"2017","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/da.23032","article-title":"Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study","volume":"37","author":"R R Kayser","year":"2020","journal-title":"Depress Anxiety"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00213-011-2347-8","article-title":"Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: A pilot study","volume":"218","author":"J E Grant","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/YIC.0000000000000382","article-title":"Tetrahydrocannabinol fails to reduce hair pulling or skin picking: Results of a double-blind, placebo-controlled study of dronabinol","volume":"37","author":"J E Grant","year":"2022","journal-title":"Int Clin Psychopharmacol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1503\/jpn.190021","article-title":"Cannabis: A potential efficacious intervention for PTSD or simply snake oil?","volume":"44","author":"A Abizaid","year":"2019","journal-title":"J Psychiatry Neurosci"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.4088\/JCP.14m09475","article-title":"Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder","volume":"76","author":"S T Wilkinson","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1017\/S003329172000197X","article-title":"Cannabis use and posttraumatic stress disorder: Prospective evidence from a longitudinal study of veterans","volume":"52","author":"J Metrik","year":"2022","journal-title":"Psychol Med"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/da.22954","article-title":"Interactive effects of PTSD and substance use on suicidal ideation and behavior in military personnel: Increased risk from marijuana use","volume":"36","author":"N P Allan","year":"2019","journal-title":"Depress Anxiety"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jad.2020.05.132","article-title":"Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder","volume":"274","author":"E M LaFrance","year":"2020","journal-title":"J Affect Disord"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/0269881119882806","article-title":"Does cannabis use modify the effect of post-traumatic stress disorder on severe depression and suicidal ideation? Evidence from a population-based cross-sectional study of Canadians","volume":"34","author":"S Lake","year":"2020","journal-title":"J Psychopharmacol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/dta.1377","article-title":"Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence","volume":"4","author":"T Passie","year":"2012","journal-title":"Drug Test Anal"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/02791072.2013.873843","article-title":"PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program","volume":"46","author":"G R Greer","year":"2014","journal-title":"J Psychoactive Drugs"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1014630","DOI":"10.3389\/fpsyt.2022.1014630","article-title":"Medical cannabis for treatment-resistant combat PTSD","volume":"13","author":"N Nacasch","year":"2022","journal-title":"Front Psychiatry"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/JCP.0000000000000180","article-title":"Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: A retrospective evaluation","volume":"34","author":"C Cameron","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1755-5949.2008.00071.x","article-title":"The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)","volume":"15","author":"G A Fraser","year":"2009","journal-title":"CNS Neurosci Ther"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40261-014-0212-3","article-title":"Preliminary, open-label, pilot study of add-on oral \u03949-tetrahydrocannabinol in chronic post-traumatic stress disorder","volume":"34","author":"P Roitman","year":"2014","journal-title":"Clin Drug Investig"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7812\/TPP\/16-005","article-title":"Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: A case report","volume":"20","author":"S Shannon","year":"2016","journal-title":"Perm J"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1089\/acm.2018.0437","article-title":"Cannabidiol in the treatment of post-traumatic stress disorder: A case series","volume":"25","author":"L Elms","year":"2019","journal-title":"J Altern Complement Med"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study","volume":"51","author":"R Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1590\/1516-4446-2021-2317","article-title":"The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event","volume":"44","author":"L M Bolsoni","journal-title":"Braz J Psychiatry"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00213-021-06043-y","article-title":"Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder","volume":"239","author":"L M Bolsoni","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"e0246990","DOI":"10.1371\/journal.pone.0246990","article-title":"The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial","volume":"16","author":"M O Bonn-Miller","year":"2021","journal-title":"PLoS One"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/mp.2013.61","article-title":"Elevated brain cannabinoid CB1 receptor availability in posttraumatic stress disorder: A positron emission tomography study","volume":"18","author":"A Neumeister","year":"2013","journal-title":"Mol Psychiatry"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/02791072.2017.1390179","article-title":"Mother of cerries, ACDC, or chocolope: Examination of the strains used by medical cannabis patients in New England","volume":"50","author":"B J Piper","year":"2018","journal-title":"J Psychoactive Drugs"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1037\/pha0000285","article-title":"The use of cannabinoids for sleep: A critical review on clinical trials","volume":"27","author":"N Kuhathasan","year":"2019","journal-title":"Exp Clin Psychopharmacol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/mdc3.13471","article-title":"Effects of nabilone on sleep outcomes in patients with Parkinson\u2019s disease: A post-hoc analysis of NMS-Nab study","volume":"9","author":"M Peball","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2147\/NSS.S340949","article-title":"Is there a place for medicinal cannabis in treating patients with sleep disorders?","volume":"14","author":"K J Maddison","year":"2022","journal-title":"What we know so far. Nat Sci Sleep"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"zsab149","DOI":"10.1093\/sleep\/zsab149","article-title":"Treating insomnia symptoms with medicinal cannabis: A randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo","volume":"44","author":"J H Walsh","year":"2021","journal-title":"Sleep"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"e13793","DOI":"10.1111\/jsr.13793","article-title":"Medicinal cannabis improves sleep in adults with insomnia: A randomised double-blind placebo-controlled crossover study","volume":"32","author":"K Ried","year":"2023","journal-title":"J Sleep Res"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00004714-198812000-00021","article-title":"Marijuana and Tourette\u2019s syndrome","volume":"8","author":"R Sandyk","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/026988119300700411","article-title":"Effective treatment of Tourette\u2019s syndrome with marijuana","volume":"7","author":"M Hemming","year":"1993","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1600-0447.1998.tb10127.x","article-title":"Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome","volume":"98","author":"K R M\u00fcller-Vahl","year":"1998","journal-title":"Acta Psychiatr Scand"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.neuropsych.16110310","article-title":"Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome","volume":"29","author":"E Abi-Jaoude","year":"2017","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.parkreldis.2018.10.004","article-title":"Single center experience with medical cannabis in Gilles de la Tourette syndrome","volume":"61","author":"A Thaler","year":"2019","journal-title":"Parkinsonism & Related Disorders"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3390\/ijms18081739","article-title":"Speechlessness in Gilles de la Tourette syndrome: Cannabis-based medicines improve severe vocal blocking tics in two patients","volume":"18","author":"E Jakubovski","year":"2017","journal-title":"Int J Mol Sci"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/ajp.156.3.495","article-title":"Treatment of Tourette\u2019s syndrome with delta-9-tetrahydrocannabinol","volume":"156","author":"K R M\u00fcller-Vahl","year":"1999","journal-title":"Am J Psychiatry"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1300\/J175v02n03_10","article-title":"Combined treatment of Tourette-syndrome with delts-9-THC and dopamine receptor antagonists","volume":"2","author":"K M\u00fcller-Vahl","year":"2002","journal-title":"J Cannabis Therap"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.psychres.2011.05.033","article-title":"Cannabinoids improve driving ability in a Tourette\u2019s patient","volume":"190","author":"A Brunnauer","year":"2011","journal-title":"Psychiatry Res"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/0091217418791455","article-title":"Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report","volume":"54","author":"E-M Pichler","year":"2019","journal-title":"Int J Psychiatry Med"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/1039856216663737","article-title":"Severe motor and vocal tics controlled with Sativex\u00ae","volume":"24","author":"D Trainor","year":"2016","journal-title":"Australas Psychiatry"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/brainsci7050047","article-title":"Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximols","volume":"7","author":"A S Kanaan","year":"2017","journal-title":"Brain Sci"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1176\/appi.neuropsych.19080178","article-title":"A phase-2 pilot study of a therapeutic combination of \u03949-tetrahydracannabinol and palmitoylethanolamide for adults with Tourette\u2019s syndrome","volume":"33","author":"M H Bloch","year":"2021","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/can.2018.0050","article-title":"Treatment of Gilles de la Tourette syndrome with cannabis-based medicine: Results from a retrospective analysis and online survey","volume":"4","author":"L M Milosev","year":"2019","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.24911\/ejmcr\/2\/11","article-title":"Delta-9-tetrahydrocannabinol for the treatment of a child with Tourette syndrome\u2014case report","volume":"2","author":"N Szejko","year":"2018","journal-title":"EJMCR"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000496355","article-title":"Vaporized cannabis is effective and well-tolerated in an adolescent with Tourette syndrome","volume":"2","author":"N Szejko","year":"2019","journal-title":"MCA"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/JCP.0b013e3181d236ec","article-title":"Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report","volume":"30","author":"A Hasan","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-2002-25028","article-title":"Treatment of Tourette\u2019s syndrome with delta 9-tetrahydrocannabinol (THC): A randomized crossover trial","volume":"35","author":"K R M\u00fcller-Vahl","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","article-title":"Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial","volume":"64","author":"K R M\u00fcller-Vahl","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/s-2001-15191","article-title":"Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance","volume":"34","author":"K R M\u00fcller-Vahl","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/sj.npp.1300047","article-title":"Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): No influence on neuropsychological performance","volume":"28","author":"K R M\u00fcller-Vahl","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1089\/can.2022.0091","article-title":"A double-blind, randomized, controlled crossover trial of cannabis in adults with Tourette syndrome","volume":"8","author":"E Abi-Jaoude","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"575826","DOI":"10.3389\/fpsyt.2020.575826","article-title":"The CANNA-TICS Study Protocol: A randomized multi-center double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders","volume":"11","author":"E Jakubovski","year":"2020","journal-title":"Front Psychiatry"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"115135","DOI":"10.1016\/j.psychres.2023.115135","article-title":"CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders \u2013 Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study","volume":"323","author":"K R M\u00fcller-Vahl","year":"2023","journal-title":"Psychiatry Res"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1055\/a-1675-3494","article-title":"Endocannabinoid modulation using monoacylglycerol lipase inhibition in Tourette syndrome: A phase 1 randomized, placebo-controlled study","volume":"55","author":"K R M\u00fcller-Vahl","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/mds.28681","article-title":"Monoacylglycerol Lipase Inhibition in Tourette syndrome: A 12-week, randomized, controlled study","volume":"36","author":"K R M\u00fcller-Vahl","year":"2021","journal-title":"Mov Disord"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajmg.b.20159","article-title":"Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene","volume":"127B","author":"D Gadzicki","year":"2004","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fgene.2020.00125","article-title":"Association of a variant of CNR1 gene encoding cannabinoid receptor 1 with Gilles de la Tourette syndrome","volume":"11","author":"N Szejko","year":"2020","journal-title":"Front Genet"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2256-0098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T18:14:51Z","timestamp":1731521691000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2256-0098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":139,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,5,7]]},"published-print":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2256-0098","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}